TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3685071

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31038216

Group type: EXPERIMENTAL
Intervention: Attachment avoidance in the intuition condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment anxiety in the intuition condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment avoidance in the deliberation condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment anxiety in the deliberation condition
Number of subjects: 0
Study: 29462471

Group type: EXPERIMENTAL
Intervention: Interceptive extraction of the deciduous canine
Number of subjects: 67
Study: 27852905

Group type: EXPERIMENTAL
Intervention: APM
Number of subjects: 341

Group type: COMPARATOR
Intervention: PT
Number of subjects: 341
Study: 24449819

Group type: EXPERIMENTAL
Intervention: Transendocardial stem cell injection (TESI) with mesenchymal stem cells
Number of subjects: 30
Study: 21950372

Group type: EXPERIMENTAL
Intervention: Pregabalin (75mg-300mg twice a day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 31
Study: 20560884

Group type: EXPERIMENTAL
Intervention: Cuffed ETT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Uncuffed ETT
Number of subjects: 70
Study: 18489451

Group type: EXPERIMENTAL
Intervention: Home visits from community nurses within 30 days of hospital discharge
Number of subjects: 166

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 166
Study: 16273751

Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct His bundle stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apical right ventricular stimulation
Number of subjects: 0
Study: 12681871

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (100 microg) every 4 hours for a maximum of two doses
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 10382948

Group type: EXPERIMENTAL
Intervention: G‐CSF starting on day 8
Number of subjects: 30

Group type: COMPARATOR
Intervention: G‐CSF starting on day 15
Number of subjects: 30
Study: 9124979

Group type: EXPERIMENTAL
Intervention: Cefpirome administered by slow intravenous infusion in a daily dose of 2 to 4 g every 12 hours depending on the disease severity.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cefpirome therapy for exacerbated severe chronic purulent bronchitis.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cefpirome treatment for mucoviscidosis.
Number of subjects: 22
Study: 1829078

Group type: EXPERIMENTAL
Intervention: Teicoplanin and ceftriaxone combination therapy (arm A)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Tri-antibiotic regimen (teicoplanin, ceftriaxone, amikacin) when fever occurred (arm B)
Number of subjects: 71
Study: 6871920

Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine gluconate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sustained-release quinidine sulfate
Number of subjects: 16
Study: 29806538

Group type: EXPERIMENTAL
Intervention: BAY 1158061 (30 mg at 14-day interval)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BAY 1158061 (60 mg at 28-day interval)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BAY 1158061 (90 mg at 14-day interval)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BAY 1158061
Number of subjects: 29
Study: 27894822

Group type: EXPERIMENTAL
Intervention: ACTdp + Standard Care (SC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 29
Study: 26446239

Group type: EXPERIMENTAL
Intervention: Ramucirumab in combination with docetaxel
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Placebo in combination with docetaxel
Number of subjects: 1253
Study: 23258932

Group type: EXPERIMENTAL
Intervention: Three individualized nutritional counselling visits by a registered dietitian complemented with three follow-up visits by general practitioners
Number of subjects: 152

Group type: COMPARATOR
Intervention: Three follow-up visits by general practitioners alone
Number of subjects: 152
Study: 21251337

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: TV viewing
Number of subjects: 1359
Study: 19302639

Group type: EXPERIMENTAL
Intervention: Epidural saline washout (30 ml saline)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no washout)
Number of subjects: 70
Study: 17969888

Group type: EXPERIMENTAL
Intervention: TCM therapy according to syndrome differentiation combined with Western medicine
Number of subjects: 279

Group type: COMPARATOR
Intervention: Western medicine by staging
Number of subjects: 279
Study: 12904089

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1094
Study: 10858688

Group type: EXPERIMENTAL
Intervention: Self-administered glycerine suppository
Number of subjects: 131
Study: 9345330

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 8384949

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure of -20 mmHg in subgroup B (10 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure of -20 mmHg in subgroup A (8 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Second bout of lower-body negative pressure in subgroup B (7 patients)
Number of subjects: 24
Study: 3528853

Group type: EXPERIMENTAL
Intervention: Human surfactant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 31282698

Group type: EXPERIMENTAL
Intervention: Placebo group (suggestion of cognitive enhancement)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no suggestion of cognitive enhancement)
Number of subjects: 2
Study: 30169547

Group type: EXPERIMENTAL
Intervention: 100mg Nimesulide immediate, intermediate and slow release tablets
Number of subjects: 0
Study: 27107395

Group type: EXPERIMENTAL
Intervention: Crossover balloon occlusion technique (CBOT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (no CBOT)
Number of subjects: 98
Study: 24885645

Group type: EXPERIMENTAL
Intervention: Physiotherapy-based gait training supported by withdrawal reflex stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy-based gait training alone (Control)
Number of subjects: 0
Study: 22717544

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Time-varying Cornell product
Number of subjects: 1280
Study: 20847699

Group type: EXPERIMENTAL
Intervention: Maraviroc or Lopinavir/Ritonavir (4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (4 weeks)
Number of subjects: 10
Study: 19491469

Group type: EXPERIMENTAL
Intervention: Stereotactic lesional surgery
Number of subjects: 11

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 11
Study: 15844733

Group type: EXPERIMENTAL
Intervention: 100 IU of recombinant FSH (Puregon)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 200 IU of recombinant FSH (Puregon)
Number of subjects: 192
Study: 12067170

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 55
Study: 10651671

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (75 or 100 microg) combined with 5 mg of isobaric bupivacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Subcutaneous saline solution (control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine combined with bupivacaine
Number of subjects: 34
Study: 8878142

Group type: EXPERIMENTAL
Intervention: Oral supplements (OS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nasogastric feeding (NG)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3
Study: 2004961

Group type: EXPERIMENTAL
Intervention: 3D treatment planning (19.8 Gy boost of a total 70.2 Gy treatment schedule)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3D treatment planning
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2D treatment planning
Number of subjects: 15
Study: 7064681

Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Benzyl penicillin
Number of subjects: 270

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 270
Study: 30797256

Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride (SnF2) dentifrice with zinc phosphate (Colgate TotalSF)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2) with zinc lactate dentifrice
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control fluoride dentifrice
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both SnF2 dentifrices
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Test dentifrice (SnF2 with zinc phosphate)
Number of subjects: 135
Study: 29597198

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist (inactive group)
Number of subjects: 20
Study: 25398398

Group type: EXPERIMENTAL
Intervention: Hyaluronan-enriched embryo transfer medium
Number of subjects: 581
Study: 23758092

Group type: EXPERIMENTAL
Intervention: ceramic‐ceramic (Yttria‐stabilized zirconia core, pressable fluorapatite glass‐ceramic)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: metal‐ceramic (palladium‐based noble alloy with press‐on leucite‐reinforced glass‐ceramic veneer)
Number of subjects: 55
Study: 22789677

Group type: EXPERIMENTAL
Intervention: Familiarity (measured by FN400 ERP component) in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarity (measured by FN400 ERP component) in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarity (measured by FN400 ERP component) in Experiment 3
Number of subjects: 0
Study: 21058478

Group type: EXPERIMENTAL
Intervention: Fire needle therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Filiform needling (common needling technique)
Number of subjects: 54
Study: 17711926

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15848557

Group type: EXPERIMENTAL
Intervention: 720 mg of oral enteric-coated mycophenolate sodium (E-MPS)
Number of subjects: 12
Study: 12669777

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg via 2-hour intravenous infusion every 3 to 4 weeks for 12 months
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study: 12080961

Group type: EXPERIMENTAL
Intervention: Active treatment (microwave thermotherapy with the Dornier Urowave)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study: 7667816

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 20 mg per day for one month
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moroxydine chloride, 1200 mg per day for one month
Number of subjects: 30
Study: 2730099

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 4
Study: 6969625

Group type: EXPERIMENTAL
Intervention: Oral BCG immunotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 39
Study: 31256647

Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene (XLP)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard polyethylene (SP)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study: 29099680

Group type: EXPERIMENTAL
Intervention: PBMT with 100 mW power output per diode (500 mW total)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PBMT with 200 mW power output per diode
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 25503625

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Active placebo (diphenhydramine)
Number of subjects: 29
Study: 23806395

Group type: EXPERIMENTAL
Intervention: V-Loc sutures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polyglactin sutures
Number of subjects: 80
Study: 21702128

Group type: EXPERIMENTAL
Intervention: Tropisetron (alpha7 nAchR agonist and 5‐HT3 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18643849

Group type: EXPERIMENTAL
Intervention: 4-hour patch application of PD P 506 A
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 2-hour patch application of PD P 506 A
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 1-hour patch application of PD P 506 A
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.5-hour patch application of PD P 506 A
Number of subjects: 140
Study: 17536077

Group type: EXPERIMENTAL
Intervention: Adjustment for factors affecting glycemia (age, sex, education, marital status, blood pressure, adiposity, hematocrit, fasting and post-glucose load glucose levels, glucose area under the curve, beta-cell function, insulin resistance)
Number of subjects: 3819

Group type: COMPARATOR
Intervention: Not applicable (comparison among racial and ethnic groups)
Number of subjects: 3819
Study: 17042145

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril twice daily)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Cetirizine (10-mg tablets once daily)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 360
Study: 12706362

Group type: EXPERIMENTAL
Intervention: 16 Gy boost
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: Boost dose for patients ≤40 years
Number of subjects: 5569

Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: Age as a factor
Number of subjects: 5569
Study: 10589637

Group type: EXPERIMENTAL
Intervention: Combination of levobupivacaine 0.25% and morphine 0.005%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levobupivacaine 0.25%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 0.005%
Number of subjects: 0
Study: 10163386

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE) - 5, 10, and 15 mg boluses to a total dose of 30 mg
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE) - 1.0 mg boluses to a maximum dose of 4 mg
Number of subjects: 1174
Study: 1678965

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg once a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propranolol (10 mg three times a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both Bisoprolol and Propranolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 24
Study: 6351901

Group type: EXPERIMENTAL
Intervention: Oral atenolol 25 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral atenolol 50 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral atenolol 100 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29355679

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks (q2w)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 26618282

Group type: EXPERIMENTAL
Intervention: Acetazolamide plus diet
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 165
Study: 24881610

Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 76
Study: 23739977

Group type: EXPERIMENTAL
Intervention: Repetition Trials (RTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternation Trials (ATs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetition Blocks (RBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternation Blocks (ABs)
Number of subjects: 0
Study: 20142520

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Laser treatment (LT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 54
Study: 18165394

Group type: EXPERIMENTAL
Intervention: 25 mcg E2
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 10 mcg E2
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 16364826

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: carvedilol 25 mg
Number of subjects: 82
Study: 12463664

Group type: EXPERIMENTAL
Intervention: Aspiration
Number of subjects: 61

Group type: COMPARATOR
Intervention: Arthrotomy
Number of subjects: 61
Study: 10504599

Group type: EXPERIMENTAL
Intervention: Double‐blind intradermal provocation/neutralization skin tests to food antigens
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strobovideolaryngoscopy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Double‐blind measurements of signs and symptoms, digital audio recordings for perceptual and acoustic analysis, aerodynamic laryngeal airflow and resistance measurements
Number of subjects: 10
Study: 8947786

Group type: EXPERIMENTAL
Intervention: Negative feedback (n = 40)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anger-out group (n = 19)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anger-in group (n = 18)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral feedback (n = 20)
Number of subjects: 60
Study: 1848721

Group type: EXPERIMENTAL
Intervention: 40 ml 1% mepivacaine with pH raised to 7.25 by adding 4 ml 8.4% NaHCO3
Number of subjects: 60

Group type: COMPARATOR
Intervention: 40 ml commercially prepared 1% mepivacaine hydrochloride solution containing 4 ml 0.9% NaCl (pH 6.0)
Number of subjects: 60
Study: 6802875

Group type: EXPERIMENTAL
Intervention: 35% CO2‐65% O2 inhalations
Number of subjects: 12

Group type: COMPARATOR
Intervention: Compressed air (placebo control)
Number of subjects: 12
Study: 31889433

Group type: EXPERIMENTAL
Intervention: Mixed hypoxic dose protocol (LHTLH)
Number of subjects: 10
Study: 31103108

Group type: EXPERIMENTAL
Intervention: Yoga intervention (8 weeks, 1 hour a day, 5 days a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-listed control group (normal routine)
Number of subjects: 60
Study: 28171856

Group type: EXPERIMENTAL
Intervention: LMA-assisted bronchoscopy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard nasal bronchoscopy
Number of subjects: 105
Study: 25936635

Group type: EXPERIMENTAL
Intervention: Propranolol (3.3 ± 3.0 mg/kg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 69
Study: 24005547

Group type: EXPERIMENTAL
Intervention: Augmented reality goggles
Number of subjects: 34

Group type: COMPARATOR
Intervention: Memory from the lecture (Control)
Number of subjects: 34
Study: 21874537

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Simvastatin 40-80 mg
Number of subjects: 178
Study: 19153939

Group type: EXPERIMENTAL
Intervention: Levo-Alpha-Acetylmethadol (LAAM)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 84
Study: 17934877

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa infusions for > or = 18 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Baseline assessment with head impulse testing (HIT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Baseline assessment with pure tone audiometry (PTA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Follow-up assessment during ERT
Number of subjects: 47
Study: 12525234

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 31
Study: 10611140

Group type: EXPERIMENTAL
Intervention: Eletriptan (25 microM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin (25 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eletriptan (5 microM and lower)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eletriptan (maximum blood concentration 0.5 microM after therapeutic dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical study (not specified)
Number of subjects: 0
Study: 9360003

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 90 mmHg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 85 mmHg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 80 mmHg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Elderly subgroup (< or = 90 mmHg)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Elderly subgroup (< or = 85 mmHg)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Elderly subgroup (< or = 80 mmHg)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg once daily)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 18790
Study: 1559314

Group type: EXPERIMENTAL
Intervention: Diltiazem (4 times daily administration)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 2996820

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Captopril + Naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 8
Study: 31655588

Group type: EXPERIMENTAL
Intervention: Village Health and Nutrition Days (VHNDs)
Number of subjects: 452